Research Dosing

Tirzepatide

🔴 IMPORTANT: Read This Before Proceeding With Dosing
Go to the Prep & Injection Guide for proper reconstitution, syringe sizing, and injection protocols. Mistakes here can compromise your research.

👉 Click here to read the Prep & Injection Guide

Tirzepatide was originally developed to treat Type-2 diabetes but has since become a leading anti-obesity medication. It is a dual agonist of the GLP-1 and GIP receptors — meaning it activates two distinct hormonal pathways to reduce appetite, improve metabolic rate, and support sustained weight loss.

Unlike its predecessor Semaglutide (which only targets GLP-1), Tirzepatide showed 5–7% more weight loss in clinical trials. Compared to Retatrutide, a triple agonist, Tirzepatide accomplished nearly the same weight loss but over a longer period (72 weeks vs. 48).

MECHANISM OF ACTION

  • GLP-1: Suppresses appetite and increases feelings of fullness after eating.
  • GIP: Promotes insulin secretion and supports energy balance through receptors in the hypothalamus.

BENEFITS

  • Average weight loss of 24.7% after 72 weeks
  • Reduces appetite and cravings
  • Enhances satiety and energy balance
  • Supports fat oxidation and metabolism
  • Improves insulin sensitivity and blood sugar control

POSSIBLE SIDE EFFECTS (often mild and temporary; affected only ~25% in trials)

  • Injection site reaction (redness, swelling, itching)
  • Nausea
  • Vomiting
  • Diarrhea
  • Constipation
  • Decreased appetite
  • Fatigue
  • Dyspepsia (indigestion)
  • Abdominal pain
  • Burping (may have sulfur smell)
  • Hair loss

RARE BUT SERIOUS RISKS

  • Thyroid C-Cell Tumors
  • Pancreatitis
  • Gastroparesis (stomach paralysis)
  • Hypoglycemia (if used with insulin)
  • Gallbladder disease
  • Kidney issues (linked to dehydration)
  • Pulmonary aspiration under anesthesia – ALWAYS disclose Tirzepatide use to surgical teams

INTERACTIONS

  • Insulin and Insulin-stimulating drugs: includes all forms of insulin, sulfonylureas (glipizide, glyburide, glimepiride), and glinides (repaglinide), due to the increased risk of hypglycemia
  • Oral medications: Tirzepatide may interfere the absorption of oral medications
  • Oral birth control medications: increases the likelihood of additive GI effects, may lead to excessive appetite suppression, and increases the risk of hypoglycemia
  • Growth hormone/GH analogs: interactions have been reported with Somatropin, Lonapegsomatropin, Somapacitan
  • Alcohol: increases the risk of hypoglycemia and worsens nausea and dehydration
  • Dehydration risk: dehydration places excessive stress on the kidneys, and may lead to kidney damage; this risk increases with concurrent use with ACE inhibitors, diuretics, ARB’s, and heart failure regimens
  • Berberine/Metformin: increased risk of hypoglycemia
  • Chromium/Insulin Sensitizers: increased risk of hypoglycemia
  • Appetite suppressants: added risk of eating disorder/anorexia
  • Stimulants: excessively diminished appetite and GI intolerance overlap
  • Large, greasy meals: increases the likelihood of nausea

PEPTIDE INTERACTIONS

SEVERE

  • Other GLP peptides: Receptor redundancy and desensitization
  • Tesamorelin: Elevated glucose levels
  • IGF-1 LR3/DES and strong ghrelin agonists (e.g. GHRP 2 and 6): may oppose or significantly amplify Tirzepatide’s metabolic signaling

MODERATE

  • IGF-1 LR3 and IGF-1 DES: Risk of hypoglycemia and rapid glucose uptake
  • CJC WITH DAC: Blunts GLP metabolic benefit
  • GHRP-2, GHRP-6, Hexarelin: Can counter appetite suppression
  • BAM-15: Watch appetite suppression and fatigue
  • LL-37: May worsen nausea and inflammation
  • Oxytocin: Monitor excessive appetite loss

CONTRAINDICATIONS

  • Do not use if pregnant or breastfeeding
  • Do not use with a personal or family history of Medullary Thyroid Carcinoma or MEN 2 (Multiple Endocrine Neoplasia)
  • Do not use if you have Type-1 diabetes, diabetic retinopathy, or severe GI disease
  • Do not use if you are allergic or hypersensitive to Tirzepatide

If you have never taken ANY GLP medication (Semaglutide/Wegovy/Ozempic, Tirzepatide/Mounjaro/Zepbound, Retatrutide, Survodutide, Mazdutide, Liraglutide):
Your starting dose is 2.5mg

*

If you have previously taken any GLP medication (Semaglutide/Wegovy/Ozempic, Tirzepatide/Mounjaro/Zepbound, Retatrutide, Survodutide, Mazdutide, Liraglutide) for at least one month at the standard starter/adaptive dose, no matter how much time has elapsed since:
Your starting dose is 5mg

RECONSTITUTION, DOSING, & RELATED INFO

TIRZEPATIDE: 10MG

RECONSTITUTION

Mix with 0.5mL (50 units) of BAC water

Dose once per week (every 7 days), always on the same day of the week

You must remain on each dose for a minimum of 4 weeks before moving to the next dose

May be taken at any time of day/night

It is not necessary to be in a fasted state to dose

2.5mg = 12 units

5 mg = 25 units

7.5mg = 36 units

10mg = 50 units

TIRZEPATIDE: 30MG

RECONSTITUTION

Mix with 1.5mL (150 units) of BAC water

Dose once per week (every 7 days), always on the same day of the week

You must remain on each dose for a minimum of 4 weeks before moving to the next dose

May be taken at any time of day/night

It is not necessary to be in a fasted state to dose

Subcutaneous Administration

2.5mg = 12 units

5 mg = 25 units

7.5mg = 36 units

10mg = 50 units

12.5mg = 62 units

15mg = 75 units

TIRZEPATIDE: 60MG

RECONSTITUTION

60MG Mix with 2.5mL (250 units) of BAC water

Dose once per week (every 7 days), always on the same day of the week

You must remain on each dose for a minimum of 4 weeks before moving to the next dose

May be taken at any time of day/night

It is not necessary to be in a fasted state to dose

Subcutaneous Administration

2.5mg = 10 units

5 mg = 21 units

7.5mg = 31 units

10mg = 42 units

12.5mg = 52 units

15mg = 62 units

STACKING SUGGESTIONS

  • AOD-9604 – enhances fat breakdown and further accelerates weight loss alongside appetite suppression
  • Tesamorelin – synergistic for fat reduction, especially visceral fat and metabolic regulation
  • Semax or Selank – manage mood and cognitive function while adjusting to appetite changes
  • NAD+ or MOTS-C – support energy, mitochondrial efficiency, and metabolism while on a caloric deficit
  • BPC-157 – beneficial for gut repair if experiencing nausea, indigestion, or stomach discomfort
  • CJC-1295 / Ipamorelin – for muscle maintenance and enhanced metabolic recovery while losing fat